![]() |
市場調查報告書
商品編碼
1348457
旋塞閥的全球市場:規模,佔有率,趨勢分析(2024年~2030年):MedCoreStopcock Market Size, Share & Trends Analysis | Global | 2024-2030 | MedCore |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
2023年,全球旋塞閥市場規模達1.751億美元,較2022年的1.657億美元成長5.7%。展望未來,預計複合年增長率 (CAGR) 為 4.9%,最終達到 2.455 億美元。目前,全球旋塞閥市場由碧迪公司(BD)和貝朗公司主導。
旋塞閥正面臨來自新興無針連接器的競爭,這些連接器已被公認為市場上的替代技術。無針連接器具有多種優點,包括改善感染控制、減少液體浪費以及提高液體管理的準確性。這些連接器變得越來越熟悉和採用,影響了傳統的旋塞閥細分市場。隨著無針連接器的日益普及,它們正在某些應用和醫療保健環境中取代傳統的旋塞閥。
2023年,碧迪公司(BD)成為全球旋塞閥市場無可爭議的領導者,鞏固了其在產業中的主導地位。BD 提供兩種重要產品。BD壓倒性的影響力不僅延伸至市佔率排名第二的北美和西歐,也延伸至全球許多區域市場。
同年,貝朗確立了世界旋塞閥領域第二大影響力競爭者的地位。著名的輸液幫浦製造專家貝朗公司採取了獨特的方法,將旋塞閥裝置與其他醫療設備捆綁在一起。許多醫院喜歡綜合採購方式,並選擇從單一製造商採購大部分輸液產品。這項戰略優勢顯著增強了貝朗在旋塞閥市場的地位,特別是在西歐,貝朗在各種醫療設備領域始終表現出色。
本報告提供全球旋塞閥市場相關調查,提供市場概要,以及各市場區隔,各地區趨勢,競爭情形等資訊。
In 2023, the worldwide stopcock market achieved a total valuation of $175.1 million, reflecting a 5.7% increase compared to the $165.7 million recorded in 2022. Projections for the upcoming period suggest a sustained growth trajectory, with a compound annual growth rate (CAGR) of 4.9%, ultimately reaching $245.5 million. Presently, the global stopcock market is under the dominance of Becton Dickinson (BD) and B. Braun.
Our comprehensive medical market research involved a thorough analysis of more than 20 stopcock companies across seven continents. Employing a rigorous methodology, we delved into market sizes, unit sales, company market shares, and generated precise forecasts.
Stopcocks are encountering competition from emerging needleless connectors, which are gaining recognition as alternative technologies in the market. Needleless connectors offer various advantages, such as improved infection control, reduced fluid wastage, and enhanced precision in fluid management. These connectors are increasingly becoming more accessible and adopted, influencing traditional segments of the stopcock market. As needleless connectors continue to gain popularity, they are gradually displacing conventional stopcocks in specific applications and healthcare settings.
In 2023, Becton Dickinson (BD) emerged as the undisputed leader in the global stopcock market, solidifying its dominant position in the industry. BD proudly offers two significant offerings: the Alaris® lipid-resistant, 3-way stopcock, and an alternative latex- and PVC-free version of this essential medical device. BD's commanding influence extends not only to North America and Western Europe, where it holds the second-largest market share, but also to numerous regional markets across the globe.
During the same year, B. Braun secured its position as the second most influential competitor in the global stopcock arena. Renowned for its expertise in infusion pump manufacturing, B. Braun adopts a distinctive approach by bundling its stopcock devices with other medical equipment. Many hospitals prefer a comprehensive sourcing approach, choosing to procure the majority of their infusion products from a single manufacturer. This strategic advantage significantly enhances B. Braun's standing in the stopcock market, particularly in Western Europe, where it consistently excels across a diverse range of medical devices.
The lower tiers of the global stopcock market landscape are predominantly occupied by smaller, localized competitors. These agile players specialize in producing straightforward, cost-effective products tailored for hospital use. Nevertheless, their market share remains modest compared to industry giants capable of bundling stopcock sales with a comprehensive suite of infusion therapy products. Notably, companies like B. Braun and Becton Dickinson, among others, reign supreme in this category, leveraging their extensive product portfolios to maintain a dominant presence.